Detalhe da pesquisa
1.
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
Antimicrob Agents Chemother
; 67(4): e0005323, 2023 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36995219
2.
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Lancet
; 399(10337): 1779-1789, 2022 05 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35378077
3.
High prevalence and incidence of gonorrhoea and chlamydia in young women eligible for HIV pre-exposure prophylaxis in South Africa and Zimbabwe: results from the HPTN 082 trial.
Sex Transm Infect
; 99(7): 433-439, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-36889914
4.
HIV RNA Screening Reduces Integrase Strand Transfer Inhibitor Resistance Risk in Persons Receiving Long-Acting Cabotegravir for HIV Prevention.
J Infect Dis
; 226(12): 2170-2180, 2022 12 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-36240386
5.
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
J Infect Dis
; 225(10): 1741-1749, 2022 05 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35301540
6.
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083.
J Infect Dis
; 224(9): 1581-1592, 2021 11 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-33740057
7.
PrEP uptake, persistence, adherence, and effect of retrospective drug level feedback on PrEP adherence among young women in southern Africa: Results from HPTN 082, a randomized controlled trial.
PLoS Med
; 18(6): e1003670, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-34143779
8.
Cabotegravir Is Not Associated With Weight Gain in Human Immunodeficiency Virus-uninfected Individuals in HPTN 077.
Clin Infect Dis
; 70(2): 319-322, 2020 01 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-31125395
9.
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.
PLoS Med
; 15(11): e1002690, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30408115
10.
Engaging men in HIV treatment and prevention.
Lancet
; 392(10162): 2334-2335, 2018 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30527600
11.
Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAACT 2017/MOCHA): a secondary analysis of a phase 1/2, multicentre, open-label, non-comparative dose-finding study.
Lancet HIV
; 11(4): e222-e232, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538161
12.
Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMPAACT 2017/MOCHA): a phase 1/2, multicentre, open-label, non-comparative, dose-finding study.
Lancet HIV
; 11(4): e211-e221, 2024 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-38538160
13.
Efficacy and safety of long-acting cabotegravir compared with daily oral tenofovir disoproxil fumarate plus emtricitabine to prevent HIV infection in cisgender men and transgender women who have sex with men 1 year after study unblinding: a secondary analysis of the phase 2b and 3 HPTN 083 randomised controlled trial.
Lancet HIV
; 10(12): e767-e778, 2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37952550
14.
Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trial.
Lancet HIV
; 10(11): e703-e712, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37783219
15.
Correction to "Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study".
ACS Pharmacol Transl Sci
; 4(4): 1462, 2021 Aug 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35783008
16.
Identification of Novel UGT1A1 Variants Including UGT1A1 454C>A through the Genotyping of Healthy Participants of the HPTN 077 Study.
ACS Pharmacol Transl Sci
; 4(1): 226-239, 2021 Feb 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33615175
17.
Brief Report: Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077.
J Acquir Immune Defic Syndr
; 85(1): 93-97, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32452972
18.
Understanding the HIV Epidemic Among MSM in Baltimore: A Modeling Study Estimating the Impact of Past HIV Interventions and Who Acquired and Contributed to Infections.
J Acquir Immune Defic Syndr
; 84(3): 253-262, 2020 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32141958
19.
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
Lancet HIV
; 7(7): e472-e481, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32497491
20.
Testing the Effectiveness and Cost-Effectiveness of a Combination HIV Prevention Intervention Among Young Cisgender Men Who Have Sex With Men and Transgender Women Who Sell or Exchange Sex in Thailand: Protocol for the Combination Prevention Effectiveness Study.
JMIR Res Protoc
; 9(1): e15354, 2020 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32012113